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Nasal polyposis often is characterized by a persistent inflammation of the sinonasal mucosa, disease recurrence after medical or
surgical intervention, and asthma comorbidity. Dysregulated complement activation may contribute to immunologic alterations
and disease. To date, there is only scattered knowledge on the source and regulation of the central complement factors in the
pathogenesis of nasal polyps. Here, we aim to study complement signatures, especially the C3-C3aR axis, and focus on cellular
sources and targets in nasal polyps. Expression of complement factors, including C3, C5, and the anaphylatoxin receptors, was
analyzed in nasal polyp tissue samples, the corresponding inferior turbinates, and healthy controls using transcriptomic
methods and protein measurements. Distinct patterns of complement expression were found in nasal polyps compared to
controls, characterized by an increased C3 activation and an increase in C3aR-bearing cells. In contrast, no difference was
shown for epithelial-dependent C3 production. Besides low intracellular C3-expression levels for lymphocytes in general, we
could identify an enlarged B lymphocyte population in nasal polyps displaying high amounts of intracellular C3. Our data
suggest a prominent role for the C3-C3aR-axis in nasal polyps and, for the first time, describe a B cell population containing
high levels of intracellular C3, suggesting a new role of B cells in the maintenance of the inflammation by complement.
1. Introduction
Chronic rhinosinusitis (CRS) is characterized by inflammatory
changes in the sinonasal mucosa persisting at least 12 weeks
and affecting 10.9% of the European population [1]. Chronic
rhinosinusitis with nasal polyps (CRSwNP) is classified as
one of the main subgroups of CRS. Nasal polyps are mostly
raising from the middle nasal meatus [2] and are histologically
characterized by lack of collagen [3], loose connective tissue
with edema, and coverage with commonly pseudostratified
respiratory epithelium [4]. Most forms of CRSwNP in patients
of the western population show a T helper 2 (Th2) polarization
with an infiltration of different inflammatory cells such as
lymphocytes and macrophages but essentially consisting of
eosinophilic granulocytes [5, 6]. Several hypotheses have been
made to unravel the development of nasal polyps including
the consideration of environmental factors such as fungi, Staph-
ylococcus aureus with biofilm formation, and other microbial
pathogens, but also host-specific factors such as an immune
barrier dysfunction and alterations in the eicosanoid pathway
[7–13]. Nevertheless, the exact most likely multifactorial mech-
anisms describing the pathogenesis, inflammatory processes, as
well as the cellular progression still remain elusive [14].
The complement system, as an important part of the
innate immunity, plays an important role in maintaining
the immune homeostasis. The system consists of fluid phase
plasma proteins and membrane-bound molecules and is
divided into three distinct pathways—the classical, lectin,
and alternative pathway [15]. Once activated, the three path-
ways lead to the formation of C3-convertases accompanied
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by C3 processing into C3b, opsonizing pathogens, and C3a,
modulating inflammatory cells. In the further outcome, C5 is
cleaved releasing C5b, the initial part for building membrane-
attack complexes (MAC) lysing target cells, and C5a, a strong
inflammatory mediator [16–18]. As the complement system
is wide-ranging, a strict and fine-tuned regulation is indispens-
able. Nasal polyposis has a large immunologic background and
especially the innate immune system is a promising field in
unraveling the undiscovered aspects of this disease. So far,
complement expression was shown to be upregulated in
CRS(wNP) patients [19–21]. Anaphylatoxins were increased
in nasal secretions of CRSwNP patients without displaying
effects on serum levels [22]. The detection of complement
activation products in tissue samples was demonstrated for
CRS without polyps [20], but even more for CRSwNP patients
suggesting a role for the classical pathway [22, 23]. Tan et al.
reviewed recently the role of B cells and antibodies in CRS
proposing a B cell-mediated classical complement activation
[24]. Thereby, the expansion of extrafollicular activated B cells
producing antibasement membrane autoantibodies leads to
complement activation and epithelial damage. Anaphylatoxins,
especially C3a being able to recruit eosinophilic granulocytes,
might possess an important immune regulatory function in
CRSwNP. The origin of higher complement load and activa-
tion still remains to be determined, whereas the immunologic
cellular infiltrate might play a role.
Therefore, we aimed to investigate the link between
complement signatures in CRSwNP, epithelial cells, and
tissue infiltrating lymphocytes, especially B cells, as a poten-
tial regulatory loop to drive the progression of inflammatory
nasal polyposis.
2. Materials and Methods
2.1. Ethics Statement. All patients were treated surgically at
the Department of Otorhinolaryngology, University Hospital
Schleswig-Holstein, Campus Lübeck, and have given their
written informed consent. The study was approved by the
local ethics committee of the University of Lübeck (approval
number 16-278) and conducted in accordance with the ethi-
cal principles for medical research formulated in the WMA
Declaration of Helsinki.
2.2. Patient Specimens. We examined tissue samples from 39
patients with CRSwNP (mean age 50.9, 29male and 10 female)
who belong to the western population, had a history of sinus-
related inflammation for more than three months and did not
respond to conservative therapy (Table 1). The nasal polyp tis-
sue and corresponding inferior turbinate tissue of the same
patient were harvested during sinus surgery to study differ-
ences between the inflamed polypoid tissue and inflamed non-
polypoid tissue. Patients were skin tested to several allergenic
substances using standardized extracts (Allergopharma
Joachim Ganzer KG) prior to surgery and classification of
CRSwNP was determined by histopathological examination.
Before surgery, all patients had been free of steroid medication
for at least four weeks.
Additionally, the inferior turbinate from twelve healthy
patients who underwent septal surgery or a septo-rhino-
plasty (mean age 30.2, 9 male and 3 female) were harvested
as noninflamed healthy controls.
2.3. Microarray. For microarray analysis, frozen tissue
samples (n = 8) were sent to Miltenyi Biotec (Bergisch
Gladbach, Germany). The mRNA was isolated using stan-
dard mRNA extraction protocols (Trizol), while the quality
was evaluated with the Agilent 2100 Bioanalyzer platform
(Agilent Technologies). RNA reaching an RNA integrity
number >6 was used [25]. Agilent Whole Human Genome
Microarrays (4×44K) were performed following manufac-
turer’s protocols. Microarray analysis was performed using R
version 3.5.2 with limma version 3.38.3 and the Affymetrix
Human Genome U95 Set annotation data (Bioconductor
package hgu95a.db version 3.8). The heatmap of genes
involved in the complement pathways was constructed using
the heatmap.2 function as implemented in the gplots package
(version 3.0.1).
2.4. Quantitative Real-Time PCR. The microarray results
were confirmed by quantitative real-time PCR (qRT-PCR)
using the samples of the investigated seven patients together
with six additional patients (n = 13) and further extended
with healthy controls (n = 12) where RNA was extracted
using the RNeasy™ Plus Mini Kit (Qiagen) following manu-
facturer’s instructions for animal tissue. The quantity and
purity of the RNA was determined using Nanodrop™ 2000
Spectrophotometer (Peqlab Biotechnologies) measuring at
260 and 280nm. The cDNA was synthesized from maximum
1μg total RNA with the RevertAid First Strand cDNA Synthe-
sis Kit (Thermo Fisher Scientific Inc.). QRT-PCR reaction
mixture consisted of 10ng cDNA, 10μL TaqMan™ Gene
Expression Mastermix (Life Technologies), and 1μL 20x Taq-
Man™ Gene Expression Assays (Life Technologies) (Table 2).
The reaction was performed as shown before [26]. All
reactions were performed in triplicate and β-actin was used
as a reference control. The ΔCt value (difference in threshold
cycles for target and β-actin) was used in the 2-ΔCt formula to
illustrate differential expression in the analyzed tissue sam-
ples. Ct values exceeding 35 cycles were assumed negative
and expression was set to zero.
2.5. Western Blot. For western blot analysis, about 100mg
frozen tissue from CRSwNP patients (n = 15) was shredded
in lysis buffer consisting of RIPA buffer (1% igepal® CA-
630/0.5% natrium deoxycholate/0.1% sodium dodecyl sulfate
(SDS) in PBS) complemented with 30μg/mL aprotinin, 1%
phosphatase-inhibitor cocktail 2, 0.57mM phenylmethylsul-
fonyl fluoride, 1μg/mL pepstatin A, and 0.5mg/mL leupep-
tin (all from Sigma-Aldrich). After incubation for one hour
on ice and centrifugation, the protein amount was deter-
mined via Bradford measurement.
Protein extracts (30-60μg) were mixed with SDS sample
buffer (0.25mM Tris-HCl pH6.8, 8% SDS, 40% Glycerol,
20% β-Mercaptoethanol, 0.004% bromophenol blue in dis-
tilled water), and incubated for 5 minutes at 95°C. Proteins
were separated by SDS-polyacrylamide gel electrophoresis
using 7.5% or 10% gels with the peqGold protein marker V
(PeqLab, VWR) added and transferred to 0.2μm
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nitrocellulose membranes (Bio-Rad) by electro blotting using
a Mini PROTEAN® Tetra Cell (Bio-Rad). The membranes
were blocked for one hour at room temperature in TRIS-
buffered saline-0.1% Tween 20 (TBS-T) containing 5%
bovine serum albumin (BSA) or 5% milk powder. Primary
antibodies (anti-C3 1 : 3000, anti-C3aR 1 : 3000, anti-C5L2
1 : 500 from Novus Biologicals; anti-C5aR1 1 : 400 from Pro-
teintech, anti-C5 1 : 100 from Acris Antibodies, anti-C3(acti-
vated) 1 : 100 from Santa Cruz Biotechnology; anti-GAPDH
and anti-βTubulin 1 : 1000 from Cell Signaling) were diluted
in 3% blocking solution and incubated over night at 4°C.
After rinsing in TBS, membranes were incubated with a
Horseradish Peroxidase linked secondary antibody (Sigma-
Aldrich) diluted 1 : 50000 in 3% blocking buffer for one hour
at room temperature. Protein bands were detected through
incubation with Amersham™ ECL™ Prime Western Blotting
Detection Reagent (GE Healthcare Life Sciences) and mea-
surement of chemiluminescence with the Fusion FX7 (Vilber
Lourmat). To control equal protein loading, membranes were
washed and immunologically stained as described above for
GAPDH or β-Tubulin. Quantitative analysis was performed
using Quantity One® 1D Analysis software, after which a
normalization of target protein to loading control followed.
2.6. Immunohistochemistry. For cryostat sectioning, several
fresh tissue probes (n = 7) were resected, embedded, directly
frozen using liquid nitrogen, and stored at -80°C. Nasal
polyp or inferior turbinate tissues were cryosectioned at 6
to 8μm with Cryostat CM 3050S (Leica Microsystems).
The sections were stained immunohistochemically using
the labelled streptavidin-biotin (LSAB) method for comple-
ment C3 (1 : 100, Novus Biologicals) and C5a (1 : 11, Acris
Antibodies). The staining procedure was conducted as it
was shown before [26]. For the exclusion of unspecific
binding, control sections were stained only with the polylink
secondary antibody. If necessary, staining intensity was
evaluated by two independent investigators and determined
with a scoring system: negative (-), weak (+), moderate (++),
and strong (+++).
2.7. Primary Single Cell Suspension. Approximately, 1 g of
fresh nasal polyp or inferior turbinate tissue (n = 10 for NP
and n = 4 for cIT) was kept overnight at 4°C in tissue storage
solutions (Miltenyi Biotech). The next day, the tissue was
shredded manually in Dulbeccos’s phosphate-buffered saline
(PBS, Life Technologies) and centrifuged for 5 minutes at
1200 g. The enzymatic digestion followed for 2 hours in
37°C shaking water bath using the multitissue dissociation
kit 1 (Miltenyi Biotech). After passing 70μm and 40μm cell
strainer (BD), the suspension was centrifuged for enzyme
removal and cells were resuspended in PBS for further
procedures.
2.8. Flow Cytometry. Cells from primary single cell suspension
were washed twice with PBS and centrifuged. First, a live-dead
stain was performed for 30minutes using Zombie-NIR™ (Bio-
Legend) providing red fluorescence (APC-Cy7 channel) of
dead cells. Afterwards, cells were washed, blocked (BD), and
stained with fluorescent-labelled primary antibodies against
extracellular antigens (one panel with anti-CD3-PE from
BD; anti-CD19-APC, anti-CD45-PerCP, anti-CD14-PE-Cy7,
anti-CD56-BV421™, and anti-CD16-BV510™ from BioLe-
gend to analyze lymphocytes; another panel with BioLegend
antibodies anti-EpCAM-AlexaFlour®647, anti-CD45-PerCP
together with anti-CD3-APC-Cy7, anti-CD19-APC-Cy7,
anti-CD14-APC-Cy7 as a dump channel for analysis of
epithelial cells) for 30 minutes in 2% BSA/PBS. For the
Table 1: Patients’ characteristics grouped by methodology. Y: yes; N: no; U: unknown.
Sample size Eosinophilic infiltrate Asthma Respiratory allergies
Y N U Y N U Y N U
Microarray 8 4 1 3 0 8 0 1 8 0
qPCR 13 6 4 3 1 12 0 3 10 0
Western blot 15 10 5 0 2 13 0 3 7 5
Immunohistochemistry 7 5 2 0 0 0 0 1 6 0
Flow cytometry 10 6 3 1 3 7 0 6 4 0
qPCR (healthy) 12 0 0 0
Table 2: TaqMan™ Gene Expression Assays.
Gene symbol Assay ID Reference sequence Length of amplicon
ACTB Hs99999903_m1 NM_001101.3 171 bp
C3 Hs00163811_m1 NM_000064.2 88 bp
C3AR1 Hs00269693_s1 NM_004054.2 82 bp
C5 Hs00156197_m1 NM_001735.2 143 bp
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exclusion of irrelevant cell subsets (CD3/CD19/CD14) during
staining procedures for epithelial cells, cells were additionally
incubated with according APC-Cy7 labelled antibodies (Bio-
Legend). After washing with PBS, cells were fixed with RBC
lysis/fixation solution (BioLegend) for 15 minutes. The
incubation with primary antibodies targeting intracellular
epitopes (anti-pan-Keratin-PE from Cell Signalling Technol-
ogy; anti-C3-AlexaFlour®488 and corresponding isotype
control from Abcam) was performed in perm/wash buffer
(BD) for 30 minutes at room temperature after 10 minutes
blocking with 5μL 2% BSA/PBS in perm/wash buffer (BD).
After washing with perm/wash buffer (BD), cells were resus-
pended in PBS and measured directly with BD FACS Canto
II (BD). Approximately, 150000 to 300000 cells were recorded
for each measurement.
For extracellular C3 staining of lymphocytes, the proce-
dure terminated after incubation of primary surface antibod-
ies at this including also anti-C3 antibody. An Ig-matched
isotype control was used for C3 together with FMO controls
to confirm gating strategies.
The gating procedure was realized as follows: during the
analysis of single living untreated cells, a population being
PE dim positive was apparent and was excluded from further
analysis in all probes. Following gating procedure, doublets
and dead cells were excluded first. CD45+ cells were then fur-
ther analyzed for lymphocyte investigation and divided into
CD3+ T cells and CD19+ B cells, whereas CD3-/CD19- were
examined for CD16 and CD56 positivity. Since no discrimi-
nation between CD56dim and CD56high was possible and no
consistent CD16 positivity was examined, NK cells were
defined as CD3-/CD19-/CD16-/CD56+. Epithelial CD45-
cells were gated for epithelial markers EpCAM (epithelial cell
adhesion molecule) and pan-Keratin before C3 examination.
For analysis and interpretations, the BD FACS Diva
Software 5.0.3 was used..
2.9. Statistical Analysis. All data are reported as mean +
standard error of themean (SEM). The analysis was done
using GraphPad® Prism version 5.0 software (GraphPad
Software). Differences between nasal polyps and correspond-
ing inferior turbinates of the same patients were analyzed
using Wilcoxon matched-pairs signed rank test or Mann–
Whitney U test in case of unequal quantities. Differences
between CRSwNP tissue and inferior turbinates of healthy
patients were calculated with the Mann–Whitney U test. p
values <0.05 were considered statistically significant.
3. Results
3.1. Complement Genes Are Differentially Expressed in Nasal
Polyps. Microarray analysis was performed using inflamed
polypoid tissue and corresponding inflamed nonpolypoid
tissue (inferior turbinate) of eight CRSwNP patients. One
patient sample showing a greater discrepancy to the others
was excluded (principle component analysis and inspection
of the data; data not shown). The expression of several com-
plement components is shown in the heatmap (Figure 1).
Remarkably, several complement regulator genes (CD59,
CD46, CD55, CLUSTERIN, VITRONECTIN, CFH, and
CFHR1-4) were upregulated in inferior turbinates compared
to nasal polyps, whereas some genes were increased in
polyps, such as genes coding for complement receptors
(CR1, CR4, CRIG); others only showed a slight increase for
polyps as genes coding for the central cascade (C3, C4, C5,
C6, C8). Also, properdin, the alternative pathway stabilizer,
was highly abundant in nasal polyps. Notably, one nasal
polyp sample seemed to be an outliner due to a more intense
upregulation in many genes (leftmost sample in Figure 1).
These results show the important differences between
nasal polyps and inferior turbinate illustrating a potential
misdirected shift in complement expression in nasal polyps
but also showing variances between the individual patients.
3.2. Central Complement Components Are Upregulated in
CRSwNP Patients Compared to Healthy Controls. Further
extending the findings of microarray experiments, the com-
plement components were tested in qRT-PCR experiments
in the tissues from thirteen CRSwNP patients. No significant
differences between nasal polyp (NP) tissue and correspond-
ing inferior turbinate (cIT) could be measured for comple-
ment factor C3, C5, and the anaphylatoxin receptors for C5a
(C5AR1 and C5L2) (Figure 2(a)). In contrast, the anaphyla-
toxin receptor for C3a (C3AR, p = 0:0007) was significantly
increased in NP compared to the cIT. Themost striking differ-
ence can be seen between CRSwNP material compared to
noninflamed control tissue of the inferior turbinate of twelve
healthy donors, as most complement genes were significantly
upregulated in nasal polyps (C5 p = 0:0004, C5AR1 p =
0:0036, C5L2 p = 0:0002, C3AR p = 0:0039) or the corre-
sponding inferior turbinate (C5 p = 0:0007, C5L2 p = 0:0007)
versus controls, supporting the finding that the inflammatory
reaction is also expanded to the inferior turbinate in patients
with CRSwNP.
Characterizing the expression of C3, C5, and the anaphy-
latoxin receptors at protein level for 15 CRSwNP patients
identified relevant end-point differences between the two
types of tissues (NP vs. cIT, Figures 2(b)–2(f)). Our data
demonstrate significantly increased expression levels of C3
(p = 0:0012), C3aR (p =   < 0:0001), and C5 (p = 0:0009) in
NP compared to the cIT (Figures 2(b)–2(d)). The receptors
for C5a on the other hand were less abundant in polyp tissues
(C5aR1, Figure 2(e)) or were not differently expressed between
the polyps and the inferior turbinates (C5L2, Figure 2(f)).
3.3. Complement C3 Activation Is Enhanced in Polyp Tissue of
CRSwNP Patients. Since the formation of C3b and C5a from
native C3/C5 is an initiation pathway-independent parame-
ter of complement activation, we analyzed C3b via Western
blotting, and since C5a was not detectable with the same
method it was analyzed via immunohistochemistry.
Significantly elevated levels of C3b were found in NP
tissues compared to cIT (Figure 3(a), p = 0:0004) which is
further cleaved to iC3b. The immunohistochemical staining
intensity for C5a was evaluated using a scoring system
[negative (-), weak (+), moderate (++), and strong (+++)]
and revealed no apparent differences between NP and cIT
(Figure 3(b)).
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An increased C3 expression and activation was demon-
strated in NP. Therefore, the subsequent step was to elucidate
the cellular source of its expression.
3.4. Complement C3 Is Located at the Epithelial Compartment
in CRSwNP Tissue. Although immunohistochemical C3
expression was partially shown in the lumen of cIT and NP
tissue, the location of C3 was often near or in the epithelial
compartment (Figure 4(a)). Therefore, epithelial cells were
analyzed in NP and cIT single cell suspensions via intracellu-
lar flow cytometry staining to identify possible differences in
the amount of C3. The AlexaFluor®488 (C3) mean fluores-
cence intensity (MFI) of CD45-/EpCAM+/pan-Keratin+ cells
was evaluated and showed no significant difference between
nasal polyps and associated inferior turbinates (Figure 4(b)).
3.5. A B Cell Subpopulation with Increased Intracellular C3 Is
Found in Nasal Polyps. As potentially infiltrating immune
cells could be a source for complement C3, single cell
suspensions of nasal tissues were permeabilized for intracel-
lular C3 analysis.
Flow cytometry results showed a low C3 expression
(C3low) in all lymphocytes (CD3+, CD19+, and CD3-/CD19-































































Figure 1: Heatmap of complement expression in nasal polyps compared to corresponding inferior turbinates after microarray analysis (n = 7).
5Journal of Immunology Research




















































































































































































































Figure 2: Complement C3, C5, and anaphylatoxin receptor expression in CRSwNP and healthy tissue. (a) The lysed tissue of nasal polyps (NP),
corresponding (cIT), and healthy inferior turbinates was analyzed for mRNA expression of complement proteins by qRT-PCR displaying mean
2-ΔCt values. Significant differences were detected for C5AR1 (NP vs. hIT p = 0:0036), C5L2 (NP vs. hIT p = 0:0002/cIT vs. hIT p = 0:0007), C5
(NP vs. hIT p = 0:0004/cIT vs. hIT p = 0:0007), C3AR (NP vs. hIT p = 0:0039/NP vs. cIT p = 0:0007).N = 12 − 13. Means with SEM are shown.
(b–f) Quantified protein expression of C3 (b, p = 0:0012), C3aR (c, p = <0:0001), C5 (d, p = 0:0009), C5aR1 (e), and C5L2 (f) comparing lysates
of NP and cIT from CRSwNP patients (n = 15) inWestern blots under reducing conditions with four representative patient samples. Means with
SEM are shown. ∗p < 0:05; ∗p < 0:01; ∗∗∗ p < 0:001.
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displaying MFI for C3 and isotype control (Figure 5(d)).
Surprisingly, a B cell population with higher intracellular C3
(C3++) was found in NPs (17:1 ± 3:9%, Figures 5(a) and
5(b)) and was significantly increased (p = 0:0196, Figure 5(c))
compared to cITs (3.0±1.4%). Additionally, these B cells
revealed an increase in cellular size compared to C3low cells
which is displayed in Figure 5(a) using forward and side scatter.
No adequate C3++ population was thereby detected for other
lymphocytes (Figures 5(a) and 5(c)). Since the used C3 anti-
body was raised against parts of the C3d amino acid sequence
of C3 (Abcam), the possibility of surface bound C3 antibody
on complement activated CD19+ B cells was ruled out via
extracellular C3 staining without permeabilization. Comparing
MFI of C3 and isotype control, no increased detection was
shown on B cells which also corresponds to the other lympho-
cytes measured displaying similar behavior and therefore no
relevant differences (Figure 5(e)).
4. Discussion
In this study, microarray analysis of tissues from nasal
polyps and the neighboring lower turbinate revealed




















































Figure 3: Complement C3 activation is higher in nasal polyps. (a) Quantified complement C3b and iC3b protein expression in lysates from
nasal polyps (NP) compared to corresponding inferior turbinates (cIT) via reducing Western blotting (n = 15, p = 0:0004) with four
representative patient samples. Means with SEM are shown. ∗∗∗ p < 0:001. (b) LSAB-staining of C5a neo-antigen in polyp and
corresponding inferior turbinate (n = 7). Representative images are shown (bar is 200μm). Staining distribution was scored as negative (-),





































Figure 4: Complement C3 is located at epithelial cells in the nasal region. (a) The distribution of complement C3 was examined for nasal
polyps and inferior turbinate with LSAB stainings. Example pictures are shown (bar is 200 μm). (b) Using flow cytometry analysis, CD45-
/EpCAM+/pan-Keratin+ cells were evaluated for MFI of AlexaFluor488® (C3, AF488) in a single cell suspension from primary CRSwNP
patient tissues, corresponding inferior turbinates (n = 4) and nasal polyps (n = 9). Means with SEM are shown.
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differences in complement gene expression pattern pointing
to a potential misdirected shift to higher complement acti-
vation in nasal polyps.
Further, we concentrated on the detection of C3 and C5
as initiation pathway independent parameters. The forma-
tion of anaphylatoxins is of great importance for inflamma-
tory responses, since they bind to their receptors (C3aR,
C5aR1) by which immune cells are recruited and the release
of inflammatory mediators is favored [16, 27, 28]. Van Zele
et al. showed significant increased levels of complement
C3a desArg and C5a desArg, the inactivated forms of C3a
and C5a, in nasal secretions of CRSwNP patients compared
to healthy donors [22]. In the context of different diseases
such as atypical hemolytic uremic syndrome or paroxysmal
nocturnal hemoglobinuria [29, 30], a dysregulated and per-
sisting complement activity was already described as part of
the inflammatory reactions. Our data of higher gene expres-
sion levels of anaphylatoxin receptors C3AR, C5AR1, and
C5L2 in CRSwNP tissues, especially for nasal polyp tissues,
compared to healthy controls is consistent with the higher
load of immune cells expressing these receptors in the chron-
ically inflamed surroundings.
In NP, an upregulated C3aR and C3 protein expression
and activation was shown compared to cIT. In nasal polyps
from individuals of the western population, the environment
is dominated by a proinflammatory Th2-based immune
response [31]. Especially the number of eosinophilic granulo-

































































































Figure 5: Larger B cells contain more intracellular C3 in nasal polyps. Polyp (n = 9) and inferior turbinate (n = 3 − 4) tissue samples were
shredded and digested to prepare single cell suspensions. After excluding doublets and dead cells, lymphocytes were pregated for CD45.
CD3+, CD19+, and CD3-/CD19-/CD16-/CD56+ immune cells were evaluated for C3 expression. (a) Gating strategy of nasal polyp with
corresponding inferior turbinate. Immune cell subsets were gated by CD19-APC vs. C3-AlexaFluor488® compared to C3-matched isotype
control. CD3+ (orange) and CD3-/CD19-/CD16-/CD56+ (green) cells are shown together in the lower part of the plots (CD19-), whereas
CD19+ cells are displayed in violet or pink (high C3 expression: C3++), and the cellular size was further displayed using FSC and SSC. (b)
Histogram of nasal polyp and corresponding inferior turbinate presenting C3-AlexaFlour488® signal for antibody (dark grey) and isotype
control (light grey) of CD45+/CD19+ B lymphocytes with C3++ population (red box). (c) The high C3 positivity (C3++) is presented as
percentage of immune cell subsets for nasal polyps (n = 9) compared to corresponding inferior turbinates (n = 3 − 4) (CD19+ cells p =
0:0196). Means with SEM are shown. ∗p < 0:05. (d) Intracellular C3 staining revealed a low C3-positivity for all cell types investigated in
both tissues (NP n = 9, cIT n = 3 − 4) shown as MFI of AlexaFluor488® (AF488, C3) for isotype and antibody whereby C3++ CD19+ cells
were excluded. Means with SEM are shown. (e) Extracellular staining of C3 without any permeabilization presented by displaying MFI of
C3 and isotype control for lymphocyte subsets in nasal polyps (N = 5). Means with SEM are shown.
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of these cells via C3aR might be of great relevance. Drouin
et al. demonstrated the importance of C3a-C3aR interaction
for asthma and its Th2 response, whereas C3aR deficiency
leads to a decrease in eosinophils and diminished Th2-
related cytokines [32]. Also, Mulligan et al. published
observations showing reduced inflammation during C3aR
inhibition in an Aspergillus fumigatus-induced CRS mouse
model [19], supporting the detected results and the impor-
tance of C3a-C3aR interaction in humans. Nevertheless,
although we could not show a prominent role for C5a and
associated C5aR-bearing cells in NP, others postulate a role
for increased MAC-formation along the epithelium and blood
vessels leading to damage and loss of function [22, 23]. There-
fore, the role of C5 activation needs to be further determined.
The upregulated burden of complement components in
nasal polyps raised the question of which cells are involved
in the complement protein syntheses. Complement produc-
tion has been described for several epithelial cells [19, 33]
to be higher in nasal polyps [19]. We could demonstrate
immunohistochemical C3 deposition at the epithelium and
in the lumen in nasal polyps, but also for the inferior turbi-
nate. Flow cytometric analyses of epithelial cells extracted
from fresh primary tissue samples showed intracellular C3,
whereas no differences could be displayed between NP and
cIT. Therefore, although an increased complement activation
might occur at epithelial areas [22, 23], the intracellular C3
amount is not enhanced in epithelial cells of nasal polyps.
For all lymphocytic subgroups analyzed, a low intracellu-
lar C3 expression (C3low) was detected in NP and cIT, coher-
ent with previous findings for various immune cells (mast
cells, monocytes, macrophages, dendritic cells, lymphocytes
[34, 35]). For T-lymphocytes, intracellular complement C3
was shown to be important sustaining homeostasis [28]. C3
in blood-derived B cells was shown to be synthesized on a
low level by the cell, but mostly being taken up from the
surrounding [28, 36, 37].
Surprisingly, we could demonstrate a CD45+/CD19+ B
cell population, making up about 17% of total B cells, with
higher intracellular C3-expression (C3++) which is signifi-
cantly increased in nasal polyps compared to inferior turbi-
nates and could not be shown consistently for other immune
subsets investigated. At the same time, increased FSC of the
C3++ B cells compared to C3low cells indicated an increased
size and/or activation. That would propose that possibly acti-
vated B cells, becoming larger during activation and differen-
tiation [38], contain detectable higher intracellular C3 levels
in nasal polyps. This would be in accordance with elevated
levels of factors playing a role in B cell proliferation, differen-
tiation into plasma cells as well as antibody diversity shown in
nasal polyps [39–42]. Even higher amounts of plasmablasts
and plasma cells together with more antibodies and autoanti-
bodies were found in nasal polyp tissue compared to controls
[24, 39, 40, 43, 44]. Therefore, the detailed characteristics of
the C3++ B cell subpopulation remain to be determined.
Although the utilized C3 antibody was not detected on the B
cell surface, the corresponding significantly more abundant
split products might additionally lead to excessive B cell acti-
vation which could be examined using C3d-specific antibod-
ies. Tan et al. recently reviewed the role of B cell activation
and antibody formation in CRS proposing a B cell-mediated
classical complement activation [24], which is supported by
others suggesting complement activation via autoantibodies
[22, 23]. In context with our results, linking activated B cells
with a higher C3 load in nasal polys, this would support an
idea of a dysregulated B cell-dependent C3 production
together with its activation in nasal polyps which potentially
might result in an interactive activation loop of B cells and
complement. Following the reports of Kremlitzka et al. [37],
another hypothesis could be that activated B cells take up
more C3 from the surrounding to modulate gene expression,
leading to possible inflammatory changes in CRSwNP. An
intracellular role for C3 in B cell activation and homeostasis,
as it was shown for T cells, has also to be considered [28].
The restricted availability of patient material and the aspect
of a certain heterogeneity using individual patient samples
describe the limitations of this study.
5. Conclusions
In summary, we have shown a C3-C3aR axis occupation in
nasal polyps together with an augmented intracellular C3
repertoire in B cells which could refer to a prominent role
for complement in disease progression. Understanding the
exact mechanisms leading to increased C3 progression would
pave the way for potential treatment options.
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